Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell LymphomaPRNewsWire • 02/04/21
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple MyelomaPRNewsWire • 01/29/21
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior TherapyPRNewsWire • 12/21/20
KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTIBusiness Wire • 12/19/20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior TherapyPRNewsWire • 12/18/20
Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 12/15/20
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple MyelomaPRNewsWire • 12/11/20
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/07/20
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/07/20
Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/01/20
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any ModificationPRNewsWire • 11/25/20
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual MeetingPRNewsWire • 11/20/20
Karyopharm Therapeutics: Current Share Price Under-Reflects The Inherent ValueSeeking Alpha • 11/13/20
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The LancetPRNewsWire • 11/13/20
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 11/04/20
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/02/20
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/02/20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company ProgressPRNewsWire • 11/02/20